1440 - Pharmaceutical giant Eli Lilly announced yesterday that the pill form of its popular weight-loss and diabetes injectables proved effective and safe in a clinical trial, pushing the company's shares up 14%. The industry has faced a surge in demand amid the popularity of drugs like Zepbound and Mounjaro and is seeking cheaper, easier-to-use alternatives to the weekly shot versions, which cost roughly $1,300 a month without insurance.
Glucagon-like peptide-1 agonists mimic a gut hormone to activate insulin production and suppress appetite (how they work). Clinical trials and customer testimony have repeatedly indicated their efficacy, with the average user seeing weight loss of at least 10% (in addition to a slew of secondary benefits).
Eli Lilly’s daily pill, known as orforglipron, resulted in average weight loss of nearly 8% over 40 weeks in hundreds of Type 2 diabetes patients, compared to a placebo decrease of 1.7%. Roughly 65% of patients also saw blood sugar levels reach a normal level. Orforglipron has no food and water restrictions, unlike Rybelsus from Novo Nordisk (the maker of Ozempic and Wegovy), which requires fasting.
No comments:
Post a Comment